Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NBI-921355
- Development stage
- Unknown
- Lead developer
- Neurocrine Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NBI-921355 is an investigational small molecule drug that acts as a selective inhibitor of voltage-gated sodium channels Nav1.2 and Nav1.6. It is being developed for the potential treatment of certain types of epilepsy, with its primary mechanism aimed at stabilizing hyperexcitable neuronal membranes to prevent seizures. The drug was originally discovered by Xenon Pharmaceuticals and is being co-developed with Neurocrine Biosciences[1][4][5]. As of early 2025, it remains in Phase 1 clinical trials for epilepsy[1][7].
02
Targets
SCN3A (Sodium channel protein type 3 subunit alpha)SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)SCN9A (Sodium channel protein type 9 subunit alpha)SCN5A (Sodium channel protein type 5 subunit alpha)SCN4A (Voltage-gated sodium channel protein type 4 subunit alpha)SCN8A (NaV1.6)
Beyond the preview
Go deeper on NBI-921355.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NBI-921355.